Cerebain Biotech And Mossakowski Medical Research Centre Sign Memorandum Of Understanding

COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech (OTCQB: CBBT) today announced that they signed a Memorandum of Understanding with the Department of Neurodegenerative Diseases, Mossakowski Medical Research Centre in Poland. The purpose of the Memorandum of Understanding is to commence testing of Cerebain’s Medical Device once development is completed.

“We look forward to working more closely with the Department of Neurodegenerative Diseases to eradicate this terrible disease.”

This agreement is the result of the efforts of former Wisconsin Governor Scott McCallum and his work with the PLUS-IP project directed by the Polish Foreign Ministry and the U.S. State Department. Governor McCallum was recently in Poland representing Cerebain at a Conference designed to address opportunities for US-Poland cooperation within Healthcare.

“The Memorandum of Understanding marks an important step forward in our collaboration with Mossakowski Medical Research Centre to treat Alzheimer’s disease,” stated Mr. Eric Clemons, President and CEO of Cerebain. “We look forward to working more closely with the Department of Neurodegenerative Diseases to eradicate this terrible disease.”

About Cerebain Biotech Corp.

Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.

Forward-Looking Statements

This news release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.